Johnson & Johnson $JNJ Shares Sold by Peoples Bank OH

Peoples Bank OH decreased its holdings in Johnson & Johnson (NYSE:JNJ) by 4.1% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 2,544 shares of the company’s stock after selling 108 shares during the quarter. Peoples Bank OH’s holdings in Johnson & Johnson were worth $389,000 at the end of the most recent reporting period.

Other institutional investors also recently bought and sold shares of the company. Highline Wealth Partners LLC grew its position in shares of Johnson & Johnson by 51.8% in the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company’s stock valued at $42,000 after purchasing an additional 86 shares during the period. Stone House Investment Management LLC acquired a new stake in Johnson & Johnson in the 1st quarter worth about $47,000. 1248 Management LLC acquired a new position in shares of Johnson & Johnson during the first quarter valued at approximately $48,000. von Borstel & Associates Inc. purchased a new position in shares of Johnson & Johnson in the first quarter valued at approximately $49,000. Finally, Harvest Fund Management Co. Ltd purchased a new stake in shares of Johnson & Johnson during the first quarter worth approximately $52,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Johnson & Johnson

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the stock in a transaction that occurred on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the completion of the transaction, the executive vice president owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. This trade represents a 24.08% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Insiders own 0.16% of the company’s stock.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Barclays lifted their target price on shares of Johnson & Johnson from $165.00 to $176.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 17th. UBS Group set a $198.00 price objective on shares of Johnson & Johnson in a research note on Friday. Weiss Ratings restated a “hold (c+)” rating on shares of Johnson & Johnson in a report on Saturday, September 27th. Bank of America increased their price target on Johnson & Johnson from $175.00 to $198.00 and gave the company a “neutral” rating in a report on Friday. Finally, The Goldman Sachs Group boosted their price objective on Johnson & Johnson from $185.00 to $186.00 and gave the stock a “buy” rating in a research note on Friday, September 19th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and nine have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus price target of $188.88.

Johnson & Johnson Trading Up 1.4%

Shares of Johnson & Johnson stock opened at $188.51 on Monday. The stock has a 50 day moving average of $176.18 and a 200 day moving average of $162.83. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. The firm has a market capitalization of $453.98 billion, a price-to-earnings ratio of 20.16, a PEG ratio of 2.40 and a beta of 0.40. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $189.78.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.68 by $0.09. The business had revenue of $23.74 billion for the quarter, compared to analyst estimates of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The company’s quarterly revenue was up 5.8% on a year-over-year basis. During the same quarter in the prior year, the company posted $2.82 EPS. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. As a group, research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Stockholders of record on Tuesday, August 26th were paid a $1.30 dividend. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date of this dividend was Tuesday, August 26th. Johnson & Johnson’s payout ratio is 55.61%.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.